Web of Science: 47 citations, Scopus: 42 citations, Google Scholar: citations,
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
Scheffler, Matthias (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Schultheis, Anne (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Teixidó, Cristina (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Michels, Sebastian (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Morales Espinosa, Daniela (Institut Germans Trias i Pujol)
Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Hartmann, Wolfgang (University Hospital of Münster (Alemanya))
Merkelbach Bruse, Sabine (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Fischer, Rieke (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Schildhaus, Hans Ulrich (University Medical Center of Göttingen (Alemanya))
Fassunke, Jana (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Sebastian, Martin (University Hospital of Frankfurt (Alemanya))
Serke, Monika (Lung Clinic Hemer (Alemanya))
Kaminsky, Britta (Bethanien Hospital (Solingen, Alemanya))
Randerath, Winfried (Bethanien Hospital (Solingen, Alemanya))
Gerigk, Ulrich (Malteser Hospital Seliger Gerhard Bonn/Rhein-Sieg (Alemanya))
Ko, Yon Dschun (Johanniter Hospital (Bonn, Alemanya))
Krüger, Stefan (Florence-Nightingale Hospital (Düsseldorf, Alemanya))
Schnell, Roland
Rothe, Achim
Kropf Sanchen, Cornelia (University Hospital Ulm (Alemanya))
Heukamp, Lukas (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Rosell, Rafael (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya))
Büttner, Reinhard (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
Wolf, Jürgen (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))

Date: 2015
Abstract: BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. PATIENTS AND METHODS:1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. RESULTS: 19 patients of 1035 evaluable (1. 8%) had OS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36. 7 months, p < 0. 001). 9 of 14 (64. 2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5. 3 years. Ten patients with ROS1-rearrangement (52. 6%) harbored additional aberrations. CONCLUSION: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
Rights: Tots els drets reservats
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Pulmons ; Càncer ; ROS1 ; Chemotherapy ; Lung cancer ; Non-small cell lung cancer ; Prognosis
Published in: Oncotarget, Vol. 6 Núm. 12 (april 2015) , ISSN 1949-2553

DOI: 10.18632/oncotarget.3387
PMID: 25868855

9 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles

 Record created 2016-07-26, last modified 2019-02-08

   Favorit i Compartir